The U.S. Department of Health and Human Services has revised the Mandatory Guidelines for Federal Workplace Drug Testing Programs.Effective October 1, 2017, testing will be expanded to include four Schedule II drugs: hydrocodone, hydromorphone, oxycodone and oxymorphone. In addition, the notice includes several minor changes including adding MDA as an initial test analyte and remove MDEA for confirmatory testing. pH cutoff levels will be raised from 3 to 4 to better identity adulterated specimens. Medical Review Officers (MRO) would also be able to recommend oral fluid collections in certain situations. Finally, employers would no longer be required to implement blind specimen testing.
- Public comments on the proposed DOT rules are due March 27, 2017.
- Rules are scheduled to be effective October 1, 2017.
- A new name will likely be issued to replace the DOT 5 Panel test. New test codes will also be required.
- Wait to test until the effective date as changes may still be made to DOT or other regulated testing.